<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468193</url>
  </required_header>
  <id_info>
    <org_study_id>CLCI699C1201</org_study_id>
    <nct_id>NCT02468193</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome</brief_title>
  <official_title>A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim is to investigate the efficacy and safety of Osilodrostat in patients with
      Cushing's syndrome due to causes other than Cushing's disease in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2015</start_date>
  <completion_date type="Anticipated">July 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in the mean Urine Free Cortisol (mUFC) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent change from baseline in the mUFC at the individual patient level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in the mUFC at Week 24 and Week 48</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Percent change from baseline in the mUFC at the individual patient level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mUFC at Week 12, Week 24 and Week 48</measure>
    <time_frame>Baseline, 12, 24 and 48 weeks</time_frame>
    <description>Absolute and percent change from baseline in the mUFC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete, partial, and overall response rate</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <description>Complete and Partial response rate Overall response rate: proportion of patients with complete or partial responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum cortisol</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <description>Absolute and percent change from baseline in morning serum cortisol at the individual patient level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum cortisol</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <description>Absolute and percent change from baseline in morning serum cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in steroid hormones</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <description>Absolute and percent change from baseline in several hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiovascular-related metabolic parameters associated with Cushing's syndrome</measure>
    <time_frame>12, 24 and 48 weeks</time_frame>
    <description>Absolute and percent change in metabolic parameters associated with Cushing's syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General safety of LCI699</measure>
    <time_frame>For 72 weeks</time_frame>
    <description>Adverse events and laboratory abnormalities will be assessed using the National Cancer Institute-Common Toxicology Criteria grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient-Reported Outcomes</measure>
    <time_frame>Baseline, 12, 24 and 48 weeks</time_frame>
    <description>Change from baseline in standardized score of Patient-Reported Outcomes will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LCI699</measure>
    <time_frame>48 weeks</time_frame>
    <description>Exposures of LCI699 in patients with Cushing's syndrome will be evaluated at the scheduled time point</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cushing's Syndrome</condition>
  <condition>Ectopic Corticotropin Syndrome</condition>
  <condition>Adrenal Adenoma</condition>
  <condition>Adrenal Carcinoma</condition>
  <condition>AIMAH</condition>
  <condition>PPNAD</condition>
  <arm_group>
    <arm_group_label>Osilodrostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osilodrostat</intervention_name>
    <description>Osilodrostat will be prescribed by the investigator. Osirodrostat 1 mg, 5 mg, 10 mg in the form of film-coated tablets will be used for oral administration</description>
    <arm_group_label>Osilodrostat</arm_group_label>
    <other_name>LCI699</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients confirmed Cushing's syndrome [i.e. ectopic corticotropin syndrome, adrenal
             adenoma, adrenal carcinoma, ACTH-Independent Macronodular Adrenal Hyperplasia (AIMAH),
             or Primary Pigmented Nodular Adrenal Dysplasia (PPNAD)]

          -  For patients on medical treatment for hypercortisolism due to Cushing's syndrome, the
             washout periods must be completed prior to baseline efficacy assessments

        Exclusion Criteria:

          -  Patients with Cushing's disease

          -  History of hypersensitivity to osilodrostat or to drugs of similar chemical classes

          -  History of malignancy of any organ system, treated or untreated, within the past 5
             years

          -  Patients receiving treatment for within 4 weeks or â‰¤5 x half-life of the agent
             (whichever is longer) before first dose of osilodrostat

          -  Patients with risk factors for QTc prolongation or Torsade de Pointes

        Other protocol defined Inclusion/Exclusion may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukushima-city</city>
        <state>Fukushima</state>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nishinomiya-city</city>
        <state>Hyogo</state>
        <zip>663 8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>245-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing's syndrome</keyword>
  <keyword>osilodrostat</keyword>
  <keyword>LCI699</keyword>
  <keyword>ectopic corticotropin syndrome</keyword>
  <keyword>adrenal adenoma</keyword>
  <keyword>adrenal carcinoma</keyword>
  <keyword>ACTH-Independent Macronodular Adrenal Hyperplasia</keyword>
  <keyword>AIMAH</keyword>
  <keyword>Primary Pigmented Nodular Adrenal Dysplasia</keyword>
  <keyword>PPNAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Adrenocortical Adenoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
    <mesh_term>ACTH Syndrome, Ectopic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

